Category: Zacks Small Cap Research

1 2 3 4 5 32 30 / 320 POSTS
By John Vandermosten, CFATSE:PMN.TO | OTC:ARFXFREAD THE FULL PMN.TO RESEARCH REPORTThird Quarter 2018 Results ProMIS Neurosciences Inc. (TSE:PMN.TO) (OTC:ARFXF) has experienced a busy quarter since our previous report providing presentations and pres ...
By Brian Marckx, CFANASDAQ:EYEG | NYSE:AGNREAD THE FULL EYEG RESEARCH REPORTQ3 Financial Results, Operating Update…EyeGate (NASDAQ:EYEG) announced Q3 financial results and provided a business update. In terms of the financials, milestone from the EGP ...
By Brian Marckx, CFANASDAQ:CEMIREAD THE FULL CEMI RESEARCH REPORTQ3 2018: Record YTD revenue, margins take a hit but should begin to rebound…Chembio (NASDAQ:CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made i ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTBusiness UpdatePart 1 of Phase 2b Dose-Ranging, Efficacy Study Successfully CompletedOn November 27, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced that it has successfully complet ...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTQ3 Results: Results Inline But FDA-Action vs. Competitors Could Create Short-Term Headwind. Long-Term Outlook Intact…Viveve (NASDAQ:VIVE) reported Q3 2018 financial results and provided ...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTBusiness UpdateRare Pediatric Disease ProgramsOn October 31, 2018, Cerecor, Inc. (NASDAQ:CERC) announced the submission of three Orphan Drug Designation (ODD) requests for three of the d ...
By John Vandermosten, CFAOTC:GOVXREAD THE FULL GOVX RESEARCH REPORTGeoVax Labs, Inc. (OTC:GOVX) filed their 3Q:18 10-Q and press release on November 8th providing an operational and financial update on the company’s performance. Several highlights we ...
By John Vandermosten, CFANASDAQ:TENXREAD THE FULL TENX RESEARCH REPORTThird Quarter 2018 ReviewDuring the third quarter Tenax Therapeutics, Inc. (NASDAQ:TENX) continued to prepare its Phase II levosimendan trial for PH-HFpEF enrollment. Efforts in th ...
By John Vandermosten, CFANASDAQ:ATRSREAD THE FULL ATRS RESEARCH REPORTAntares Pharma, Inc. (NASDAQ:ATRS) reported third quarter results on November 6th posting revenue growth of 19% and achieving a quarterly sales record for the company. Earnings los ...
By John Vandermosten, CFANASDAQ:LPCNREAD THE FULL LPCN RESEARCH REPORT3Q:18 Operational and Financial ResultsLipocine (NASDAQ:LPCN) filed its 3Q:18 10-Q and posted its earnings release on November 7, 2018 reporting net loss per share of ($0.12). Thes ...
1 2 3 4 5 32 30 / 320 POSTS